Drug Overview:

Cabozantinib-s-malate, marketed as the potent multitargeted “smart drug” and targeted therapy Cabometyx/Cometriq, represents a paradigm shift in precision oncology for advanced solid tumors driven by dysregulated kinase signaling pathways. This oral small-molecule inhibitor simultaneously suppresses multiple receptor tyrosine kinases critical for tumor proliferation, angiogenesis, metastasis, and immune evasion, delivering superior progression-free survival benefits in VEGF therapy-refractory cancers across renal cell carcinoma, hepatocellular carcinoma, and thyroid malignancies prevalent in US and European patient populations.

Generic name: Cabozantinib-s-malate
US Brand names: Cabometyx® (20, 40, 60 mg tablets for RCC/HCC/DTC); Cometriq® (20 mg capsules for MTC)
Drug Class: Multikinase inhibitor (targeted therapy against VEGFR2/3, MET, RET, AXL, KIT, ROS1, TRKB, TIE2)
Route of Administration: Oral (tablets/capsules on an empty stomach)
FDA Approval Status: Initial approval November 2012 (Cometriq® medullary thyroid cancer); expanded November 2016 (Cabometyx® advanced RCC); January 2021 (HCC + atezolizumab); 2025 (radioactive iodine-refractory differentiated thyroid cancer post-TKI)

What Is It and How Does It Work? (Mechanism of Action)

Cabozantinib-s-malate exerts its targeted therapy effects as a potent ATP-competitive inhibitor binding the kinase domains of multiple receptor tyrosine kinases, preventing ligand-induced dimerization, autophosphorylation, and activation of convergent oncogenic signaling cascades. This “smart drug” uniquely disrupts the tumor-stroma-immune axis through simultaneous angiogenesis blockade, epithelial-mesenchymal transition (EMT) inhibition, and enhanced immune infiltration.

VEGFR2/3 inhibition (IC50 0.035 nM): Blocks VEGF-A/C/D ligand binding → prevents PLCγ1-PKC-MAPK/ERK and PI3K-AKT-mTOR pathway activation in endothelial cells → inhibits vascular permeability/proliferation/migration, starving hypoxic tumors
MET/AXL blockade (IC50 1.3/7 nM): Disrupts HGF/SF and Gas6 ligand signaling → inhibits FAK/Src-mediated focal adhesion turnover, suppresses EMT transcription factors (Snail/Slug/Twist), prevents tumor invasion/metastasis
RET inhibition (IC50 5.2 nM): Targets mutated RET fusions (M918T/C634) → blocks ligand-independent constitutive dimerization → halts RAS-RAF-MEK-ERK and PI3K-AKT cascades driving thyroid neuroendocrine proliferation
Additional RTKs (KIT/TRKB/ROS1 IC50 4-40 nM): Suppresses SCF-induced mast cell recruitment, neural invasion (TRKB), and fusion-driven oncogenesis (ROS1); modulates TAM receptors enhancing macrophage M2→M1 polarization
Convergent effects: Downregulates mTORC1/2 → G1/S arrest via 4EBP1/eIF4E; upregulates pro-apoptotic BIM/PUMA; normalizes tumor vasculature improving immunotherapy penetration

FDA Approved Clinical Indications

Cabozantinib-s-malate demonstrates broad FDA approvals exclusively for advanced refractory solid tumors, with emerging biomarkers (MET amplification, RET fusions) predicting exceptional responses in precision medicine frameworks.

Oncological uses:

Advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy or as first-line monotherapy
Unresectable, locally advanced, or metastatic hepatocellular carcinoma (HCC) in combination with atezolizumab following prior sorafenib
Progressive, metastatic medullary thyroid cancer (MTC)
Radioactive iodine-refractory differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy.

Non-oncological uses:

None

Dosage and Administration Protocols

Continuous daily oral dosing requires strict fasting conditions (1 hour before/2 hours after meals) to optimize bioavailability; sequential dose reductions (60→40→20 mg) manage >80% of grade 3+ toxicities effectively.

Patient Population	Standard Dose	Frequency	Dose Adjustments
RCC monotherapy	60 mg (three 20 mg tablets)	Orally once daily continuous	First reduction: 40 mg; second: 20 mg; permanent discontinue intolerable Grade 4
HCC + atezolizumab	60 mg	Once daily continuous	Hepatic Child-Pugh A: full dose; B: start 40 mg; C contraindicated
MTC (Cometriq capsules)	140 mg (7 × 20 mg)	Once daily (4 weeks on/2 off historical)	Strong CYP3A4 inducers: increase 40 mg (max 80 mg); QTc >500 ms: hold/reduce
Renal Impairment	No adjustment	CrCl ≥30 mL/min	CrCl <30: monitor, no data
Hepatic Impairment	Child-Pugh A: 60 mg; B: 40 mg	Same	C: contraindicated

Clinical Efficacy and Research Results

Phase 3 METEOR (RCC; NCT01865747), COSMIC-321 (HCC; NCT03713593), and CheckMate 9ER (RCC+nivo; NCT03141177) trials with 2020-2025 mature data established survival standards; CONTACT-02 (mCRPC 2025) expands indications.

Trial/Indication	PFS Benefit	OS Benefit	ORR
METEOR (RCC 2L)	21.4 vs 7.4 mo (HR 0.51)	21.4 vs 16.5 mo (HR 0.66)	17% vs 3%
COSMIC-321 (HCC)	6.8 vs 4.2 mo (HR 0.60)	15.4 vs 8.6 mo (HR 0.69)	11% vs 2%
CheckMate 9ER (RCC 1L+nivo)	NR vs 11.9 mo (HR 0.51)	2-yr 79.7% vs 68.8%	55.7% vs 27.1%

Safety Profile and Side Effects

Black Box Warning:

Severe hemorrhage (including fatal GI bleeding) and arterial/venous thromboembolic events (stroke, MI, PE) reported; GI perforation/fistula risk elevated. Discontinue for life-threatening hemorrhage; monitor BP closely.

Common Side Effects (>10%)

Adverse Event	Incidence	Management
Hypertension	36-74%	ACEi/ARB titration <140/90 mmHg; amlodipine add-on
Diarrhea	42-74%	Loperamide 4 mg stat + 2 mg PRN (≤16 mg/day); hold Grade 3+
Fatigue	56%	Scheduled rest; dose interruption Grade 3+
PPE/rash	35-57%	Urea 10-20% cream BID prophylaxis; doxycycline 100 mg BID
Weight loss	25-48%	Protein supplements; dietician referral <10% loss

Serious Adverse Events

Hemorrhage (3-10% Grade 3/4; hold Grade 3, discontinue Grade 4; urgent endoscopy for melena/hematemesis)
Thromboembolism (3-7% VTE/1-3% arterial; baseline D-dimer; LMWH if cancer-associated thrombosis)
GI perforation/fistula (1-3%; abdominal CT, NPO, surgical consult; permanent discontinuation)
Hepatotoxicity (3-9% Grade 3/4 ALT/AST; weekly LFTs first 8 weeks, hold >8x ULN)

Patient Management and Practical Recommendations

Proactive hypertension/PPE/hepatotoxicity management sustains >70% dose intensity; multidisciplinary cardio-onco/derm/vascular support essential for long-term adherence.

Pre-treatment Tests

BP (target <140/90), ECG (QTcF <450/470 ms M/F), TTE (LVEF >50%)
CBC, CMP (LFTs/bilirubin), UA (1+ protein OK), TSH/FT4, dental evaluation
Urine/serum pregnancy test (Category D teratogen)

Precautions During Treatment

Weekly BP/LFTs/CBC/UA first 8 weeks → biweekly; hold Grade 3+ tox (resume 40 mg)
Avoid strong CYP3A4 perpetrators; monitor dentition (bisphosphonate osteonecrosis risk)
ECG if syncope, palpitations, concomitant QT drugs

Do’s and Don’ts

Do take 1h fasted with ≥8 oz water; consistent daily timing
Do elevate legs, compression stockings (edema 40%); moisturize bid PPE prevention
Don’t eat 2h before/1h after; grapefruit juice
Don’t breastfeed during +4 months post-therapy

Legal Disclaimer

This guide provides general information about cabozantinib-s-malate and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult qualified healthcare providers for individualized recommendations considering complete clinical profiles, comorbidities, and guideline updates. Treatment decisions must balance risks/benefits; this content neither endorses nor contraindicates specific therapies.